Get the Stockscreener App
61.36
5.69%
-3.70
After Hours:
61.36
Guardant Health Inc stock is traded at $61.36, with a volume of 4.70M.
It is down -5.69% in the last 24 hours and up +38.85% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$65.06
Open:
$60
24h Volume:
4.70M
Relative Volume:
1.95
Market Cap:
$7.65B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-14.47
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
-4.82%
1M Performance:
+38.85%
6M Performance:
+47.93%
1Y Performance:
+151.99%
1-Day Range:
$57.50
$61.48
1-Week Range:
$57.50
$68.00
52-Week Range:
$20.14
$68.00
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
61.36 | 8.29B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
489.49 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
199.03 | 145.92B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
640.44 | 51.16B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
128.48 | 35.50B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
184.08 | 31.24B | 15.70B | 1.24B | 2.01B | 6.91 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Liquid Biopsy in Cancer Diagnostics Market to Witness Robust ~17% CAGR Expansion by 2032 | DelveInsight - Barchart.com
Is Guardant Health Inc. stock ready for a breakoutPortfolio Performance Summary & Stepwise Trade Execution Plans - Newser
Analyzing recovery setups for Guardant Health Inc. investors2025 Top Gainers & Risk Managed Trade Strategies - Newser
How to recover losses in Guardant Health Inc. stockPortfolio Update Summary & Stepwise Swing Trade Plans - Newser
Multi asset correlation models including Guardant Health Inc.Options Play & Daily Profit Focused Stock Screening - Newser
Is Guardant Health Inc. showing signs of accumulationEarnings Summary Report & Entry Point Confirmation Alerts - Newser
Guardant Health Inc. stock daily chart insightsPortfolio Profit Report & Safe Capital Growth Tips - Newser
Is It Too Late to Sell Guardant Health Inc.2025 Big Picture & Daily Technical Forecast Reports - beatles.ru
Automated trading signals detected on Guardant Health Inc.Weekly Gains Report & Capital Efficiency Focused Strategies - Newser
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands - PR Newswire
Will Guardant Health Inc. stock split in the near futureMarket Weekly Review & Weekly Momentum Picks - Newser
Is GH's Q1 2025 forecast achievable? - AInvest
Advanced analytics toolkit walkthrough for Guardant Health Inc.Analyst Downgrade & Weekly Top Gainers Alerts - Newser
Cyted Health’s $44M Series B: A Strategic Bet on Early Cancer Detection and Global Expansion - AInvest
Liquid Biopsy Market Trends and Industry Forecast to 2030 - GlobeNewswire
Liquid Biopsy Market Trends and Industry Forecast to 2030 Featuring Strategic Analysis of Natera, Guardant Health, Myriad Genetics, Illumina, and Roche Among Others - Yahoo Finance
Will Guardant Health Inc. see short term momentumTrade Volume Summary & Growth Focused Stock Reports - Newser
What’s the analyst consensus on Guardant Health Inc.Rate Cut & Free Real-Time Market Sentiment Alerts - خودرو بانک
How to read the order book for Guardant Health Inc.Market Growth Report & Risk Managed Investment Entry Signals - Newser
Is Guardant Health Inc. impacted by rising ratesQuarterly Profit Review & Smart Money Movement Alerts - khodrobank.com
Will Guardant Health Inc. bounce back from current supportJuly 2025 PreEarnings & Intraday High Probability Setup Alerts - Newser
What to do if you’re stuck in Guardant Health Inc.Portfolio Growth Summary & Capital Efficiency Focused Ideas - Newser
Live market analysis of Guardant Health Inc.Dividend Hike & Stepwise Swing Trade Plans - Newser
Signal strength of Guardant Health Inc. stock in tech scannersJuly 2025 Market Mood & High Yield Stock Recommendations - Newser
Guardant Health Inc. stock prediction for this weekTreasury Yields & Technical Analysis for Trade Confirmation - Newser
Using flow based indicators on Guardant Health Inc.Weekly Trend Summary & Risk Controlled Stock Pick Alerts - Newser
Will Guardant Health Inc. Bounce From 52 Week Low getLinesFromResByArray error: size == 0 - 더경남뉴스
Guardant Health Inc. stock outlook for YEARForecast Cut & Expert Curated Trade Setup Alerts - Newser
Will Guardant Health Inc. stock recover after recent drop2025 Support & Resistance & Long-Term Growth Stock Strategies - Newser
Guardant Health’s Strategic Moves and Analyst Confidence Propel Market Potential - StocksToTrade
Technical signs of recovery in Guardant Health Inc.2025 Retail Activity & Low Drawdown Trading Techniques - Newser
Can machine learning forecast Guardant Health Inc. recoveryEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
Backtesting results for Guardant Health Inc. trading strategiesPortfolio Growth Summary & Free Risk Controlled Daily Trade Plans - Newser
Is Guardant Health Inc. stock showing strong momentumWeekly Trading Summary & Expert Approved Trade Ideas - sundaytimes.kr
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Guardant Health Inc Stock (GH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saia John G. | Chief Legal Officer |
Sep 01 '25 |
Option Exercise |
0.00 |
264 |
0 |
45,087 |
| Kalia Kumud | Chief Information Officer |
Sep 01 '25 |
Option Exercise |
0.00 |
711 |
0 |
19,211 |
| Chudova Darya | Chief Technology Officer |
Sep 01 '25 |
Option Exercise |
0.00 |
316 |
0 |
81,610 |
| Krognes Steve E. | Director |
Aug 31 '25 |
Option Exercise |
0.00 |
155 |
0 |
18,128 |
3.32%
0.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):